Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation treatment with combination pyrimidine nucleosides in TK2 deficiency
2023-510427-29-00Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of 2'-deoxycytidine and doxribtimine in thymidine kinase 2 deficiency (TK2D), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of TEAEs leading to study drug withdrawal. Started Sep 2019; status: completed.
02
Drugs
2'-deoxycytidinedoxribtimine
03
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on 2023-510427-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510427-29-00.